Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Summary
This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of soft tissue sarcoma, not including angiosarcoma, will be enrolled on study. The primary tumor site must be deemed to be cutaneous or dermal in the opinion of the treating investigator (note the primary tumor site does NOT need to be present at the time of screening, i.e., may have been previously resected but recurred and/or metastasized). * Participants must have metastatic or advanced disease which could include recurrent, unresect…
Interventions
- DrugPembrolizumab
Outpatient infusion
Locations (3)
- Moffitt Cancer CenterTampa, Florida
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio
- MD Anderson Cancer CenterHouston, Texas